Treatment of c9ftd/als by targeting rna expanded repeat sequences

Abstract

A repeat expansion in C90RF72 causes frontotemporal dementia and amyotrophic lateral sclerosis (c9FTD/ALS). RNA of the expanded repeat (r(GGGGCC) exp ) forms nuclear foci or undergoes repeat-associated non-ATG (RAN) translation producing “c9RAN proteins”. Since neutralizing r(GGGGCC) exp could inhibit these potentially toxic events, we sought to identify small molecule binders of r(GGGGCC)exp, Chemical and enzymatic probing of r(GGGGCC) 8 indicate it adopts a hairpin structure in equilibrium with a quadruplex structure, Using this model, bioactive small molecules targeting r(GGGGCC) exp were designed arid found to significantly inhibit RAN translation and foci formation in cultured cells expressing r(GGGGCC) 66 and neurons trans-differentiated from fibroblasts of repeat expansion carriers. Finally, we show that poly(GP) c9RAN proteins are specifically detected in c9ALS patient cerebrospinal fluid. Our findings highlight r(GGGGCC) exp -binding small molecules as a possible C9FTD/ALS therapeutic, and suggest c9RAN proteins could potentially serve as a pharmacodynamic biomarker to assess efficacy of therapies that target r(GGGGCC) exp .

What is claimed is: 
     
         1 . A compound of formula 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . A method of inhibiting repeat-associated non-ATG (RAN) translation and foci formation in cultured cells expressing r(GGGGCC) 66  and neurons trans-differentiated from fibroblasts of repeat expansion carriers, comprising contacting the cells with an effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof. 
     
     
         3 . A method of treating a patient afflicted with ALS or FTD, comprising administering to the patient an effective dose of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof. 
     
     
         4 . A pharmaceutical composition comprising a compound of  claim 1  and a pharmaceutically acceptable excipient.